青霉胺治疗与硬皮病中的间质性肺疾病。一项长期随访研究。

D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study.

作者信息

de Clerck L S, Dequeker J, Francx L, Demedts M

出版信息

Arthritis Rheum. 1987 Jun;30(6):643-50. doi: 10.1002/art.1780300607.

Abstract

Sequential lung function tests were performed on 17 scleroderma patients who were treated with D-penicillamine (DP) (total of 66 treatment years) and on 10 control scleroderma patients who were not treated or were treated with low-dose prednisone (total of 25 treatment years). Cusum plots showed significant differences between the 2 groups in their cumulative changes in carbon monoxide diffusing capacity (DLCO) (P less than 0.005) and in DLCO/lung volume (P less than 0.02). The end value of the DLCO was greater than 10% lower than the initial value in 3 of the 17 DP-treated patients versus 5 of the 10 control patients (P less than 0.01, Fisher's exact probability test); in 3 DP-treated patients and 8 control patients (P less than 0.003, Fisher's exact probability test), the end value of the DLCO/lung volume was greater than 10% lower than the initial value. We conclude that DP has a beneficial effect on interstitial lung disease in patients with scleroderma.

摘要

对17例接受青霉胺（DP）治疗（总计66个治疗年）的硬皮病患者以及10例未接受治疗或接受小剂量泼尼松治疗（总计25个治疗年）的对照硬皮病患者进行了序贯肺功能测试。累积和图显示，两组在一氧化碳弥散量（DLCO）的累积变化（P<0.005）以及DLCO/肺容积方面（P<0.02）存在显著差异。17例接受DP治疗的患者中有3例DLCO的终值比初始值低10%以上，而10例对照患者中有5例（P<0.01，Fisher精确概率检验）；在3例接受DP治疗的患者和8例对照患者中（P<0.003，Fisher精确概率检验），DLCO/肺容积的终值比初始值低10%以上。我们得出结论，DP对硬皮病患者的间质性肺病有有益作用。